和鉑醫藥-B(02142.HK):HBM9033臨牀試驗啟動獲美國FDA新藥研究許可
格隆匯8月28日丨和鉑醫藥-B(02142.HK)宣佈,公司已獲美國食品及藥物監督管理局(FDA)的新藥研究申請許可("IND")在美國啟動首個抗體偶聯藥物("ADC")項目HBM9033的臨牀試驗。該試驗為一項評估HBM9033在晚期實體瘤患者中的安全性、耐受性、藥代動力學和抗腫瘤活性的I期研究。
HBM9033是我們首個進入臨牀階段的ADC資產。建基於HCAb PLUSTM平台在ADC領域的廣泛應用,我們已建立ADC生態系統,使內部開發與外部合作產生協同效應。隨着合作伙伴與我們取得迅速進展,我們將繼續加大力度積極推動在ADC領域的全球佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.